Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Common Equity (2016 - 2025)

Lisata Therapeutics' Common Equity history spans 13 years, with the latest figure at $14.6 million for Q4 2025.

  • For Q4 2025, Common Equity fell 50.2% year-over-year to $14.6 million; the TTM value through Dec 2025 reached $14.6 million, down 50.2%, while the annual FY2025 figure was $14.6 million, 50.2% down from the prior year.
  • Common Equity reached $14.6 million in Q4 2025 per LSTA's latest filing, down from $17.4 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $60.7 million in Q1 2023 to a low of $14.6 million in Q4 2025.
  • Average Common Equity over 3 years is $36.7 million, with a median of $35.7 million recorded in 2024.
  • Peak YoY movement for Common Equity: decreased 29.59% in 2024, then tumbled 50.2% in 2025.
  • A 3-year view of Common Equity shows it stood at $47.9 million in 2023, then tumbled by 38.79% to $29.3 million in 2024, then crashed by 50.2% to $14.6 million in 2025.
  • Per Business Quant, the three most recent readings for LSTA's Common Equity are $14.6 million (Q4 2025), $17.4 million (Q3 2025), and $20.8 million (Q2 2025).